• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.

作者信息

Awad Mark M, Hammerman Peter S

机构信息

Dana-Farber Cancer Institute, Boston, MA.

Dana-Farber Cancer Institute, Boston, MA

出版信息

J Clin Oncol. 2015 Jun 20;33(18):1993-4. doi: 10.1200/JCO.2015.61.4172. Epub 2015 Apr 27.

DOI:10.1200/JCO.2015.61.4172
PMID:25918290
Abstract
摘要

相似文献

1
Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.肺癌和肾癌中PD-1抑制的持久反应以及对预测性生物标志物的持续探索。
J Clin Oncol. 2015 Jun 20;33(18):1993-4. doi: 10.1200/JCO.2015.61.4172. Epub 2015 Apr 27.
2
Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.抗程序性细胞死亡蛋白1（PD-1）抗体纳武单抗在具有肉瘤样和横纹肌样特征的乳头状肾细胞癌中引发显著且快速的反应。
Eur Urol. 2015 Nov;68(5):912-4. doi: 10.1016/j.eururo.2015.07.008. Epub 2015 Jul 18.
3
In focus: bevacizumab for renal cell carcinoma.聚焦：贝伐单抗用于治疗肾细胞癌。
Clin Adv Hematol Oncol. 2005 Jan;3(1):68-9.
4
The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.非小细胞肺癌和肾细胞癌创新治疗的期权价值。
Am J Manag Care. 2017 Oct 1;23(10):e340-e346.
5
Durable Responses Achieved with AM0010.采用 AM0010 实现持久应答。
Cancer Discov. 2016 Dec;6(12):OF4. doi: 10.1158/2159-8290.CD-NB2016-125. Epub 2016 Nov 1.
6
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.纳武单抗和派姆单抗：可互换的抗程序性细胞死亡蛋白1（PD-1）单克隆抗体。
Semin Oncol. 2017 Apr;44(2):132-135. doi: 10.1053/j.seminoncol.2017.06.007. Epub 2017 Jul 13.
7
[Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer].[用于治疗黑色素瘤和其他癌症的免疫检查点抑制剂的不良反应]
Presse Med. 2017 Sep;46(9):808-817. doi: 10.1016/j.lpm.2017.05.032. Epub 2017 Jul 3.
8
Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.乳腺癌、非小细胞肺癌、黑色素瘤和肾细胞癌脑转移的全身治疗：文献综述。
Cancer Treat Rev. 2014 Sep;40(8):951-9. doi: 10.1016/j.ctrv.2014.05.007. Epub 2014 May 27.
9
FDA Approves Two New Indications and Dosage Form for Pembrolizumab.美国食品药品监督管理局批准帕博利珠单抗的两项新适应症及剂型。
Oncology (Williston Park). 2019 May 14;33(5):186.
10
Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.抗 PD-1/PD-L1 治疗转移性肾细胞癌的放射异质性反应。
Cancer Immunol Res. 2016 Jan;4(1):12-7. doi: 10.1158/2326-6066.CIR-15-0197. Epub 2015 Nov 20.

引用本文的文献

1
PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.基于泛凋亡的分子亚型和 HPAN 指数可预测肝细胞癌的治疗反应和生存。
Front Immunol. 2023 Jun 15;14:1197152. doi: 10.3389/fimmu.2023.1197152. eCollection 2023.
2
Comprehensive Genomic Characterization of Tumor Microenvironment and Relevant Signature in Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌肿瘤微环境的综合基因组特征及相关特征分析
Front Oncol. 2022 May 16;12:749119. doi: 10.3389/fonc.2022.749119. eCollection 2022.
3
Retrospective analysis of the prognostic value of PD-L1 expression and F-FDG PET/CT metabolic parameters in colorectal cancer.
结直肠癌中PD-L1表达及F-FDG PET/CT代谢参数预后价值的回顾性分析
J Cancer. 2020 Feb 25;11(10):2864-2873. doi: 10.7150/jca.38689. eCollection 2020.
4
Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.不同错配修复基因状态的结直肠癌患者的循环淋巴细胞、肿瘤浸润淋巴细胞上的PD-L1表达及生存情况
J Cancer. 2019 Apr 5;10(7):1745-1754. doi: 10.7150/jca.25187. eCollection 2019.
5
A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.一项利用激光捕获显微切割和反相蛋白质微阵列探索人类前列腺癌肿瘤微环境分子结构的初步研究。
Mol Oncol. 2016 Dec;10(10):1585-1594. doi: 10.1016/j.molonc.2016.09.007. Epub 2016 Oct 14.
6
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.程序性细胞死亡蛋白1（PD-1）和PD-配体1（PD-L1）在大肠癌细胞及肿瘤浸润淋巴细胞中的表达对结直肠癌的预后影响
Mol Cancer. 2016 Aug 24;15(1):55. doi: 10.1186/s12943-016-0539-x.
7
PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.程序性死亡蛋白1（PD1）阻断增强体外扩增的自然杀伤细胞对骨髓瘤细胞的细胞毒性。
Oncotarget. 2016 Jul 26;7(30):48360-48374. doi: 10.18632/oncotarget.10235.
8
Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer.程序性死亡配体1（PD-L1）免疫组化表达在结直肠癌中的意义
Mol Diagn Ther. 2016 Apr;20(2):175-81. doi: 10.1007/s40291-016-0188-1.
9
Immunotherapy for lung cancer.肺癌的免疫疗法。
Transl Lung Cancer Res. 2015 Dec;4(6):675-7. doi: 10.3978/j.issn.2218-6751.2015.12.07.
10
Opportunities and challenges in combination gene cancer therapy.联合基因癌症治疗中的机遇与挑战。
Adv Drug Deliv Rev. 2016 Mar 1;98:35-40. doi: 10.1016/j.addr.2015.12.005. Epub 2015 Dec 23.